These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 29053849)

  • 41. Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized, Double-Blind Trials.
    Rink L; Braun C; Bschor T; Henssler J; Franklin J; Baethge C
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29873954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis.
    Krause M; Gutsmiedl K; Bighelli I; Schneider-Thoma J; Chaimani A; Leucht S
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1003-1022. PubMed ID: 31327506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amitriptyline versus placebo for major depressive disorder.
    Leucht C; Huhn M; Leucht S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009138. PubMed ID: 23235671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients?
    Danielak D
    Expert Opin Pharmacother; 2021 Jun; 22(9):1167-1177. PubMed ID: 33650935
    [No Abstract]   [Full Text] [Related]  

  • 45. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.
    Keefe RSE; Nomikos G; Zhong W; Christensen MC; Jacobson W
    Int J Neuropsychopharmacol; 2018 May; 21(5):442-447. PubMed ID: 29546401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
    Mills NT; Sampson E; Fourrier C; Baune BT
    Int J Neuropsychopharmacol; 2021 Apr; 24(4):314-321. PubMed ID: 33269395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis.
    Furukawa TA; Salanti G; Atkinson LZ; Leucht S; Ruhe HG; Turner EH; Chaimani A; Ogawa Y; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Suganuma A; Watanabe N; Stockton S; Geddes JR; Cipriani A
    BMJ Open; 2016 Jul; 6(7):e010919. PubMed ID: 27401359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in Neuropsychological Testing.
    Jaeger J
    J Clin Psychopharmacol; 2018 Oct; 38(5):513-519. PubMed ID: 30124583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis.
    Vernon JA; Grudnikoff E; Seidman AJ; Frazier TW; Vemulapalli MS; Pareek P; Goldberg TE; Kane JM; Correll CU
    Schizophr Res; 2014 Nov; 159(2-3):385-94. PubMed ID: 25240772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis.
    Tansey KE; Guipponi M; Perroud N; Bondolfi G; Domenici E; Evans D; Hall SK; Hauser J; Henigsberg N; Hu X; Jerman B; Maier W; Mors O; O'Donovan M; Peters TJ; Placentino A; Rietschel M; Souery D; Aitchison KJ; Craig I; Farmer A; Wendland JR; Malafosse A; Holmans P; Lewis G; Lewis CM; Stensbøl TB; Kapur S; McGuffin P; Uher R
    PLoS Med; 2012; 9(10):e1001326. PubMed ID: 23091423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
    Chokka P; Bougie J; Rampakakis E; Proulx J
    CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic reviews of randomised clinical trials examining the effects of psychotherapeutic interventions versus "no intervention" for acute major depressive disorder and a randomised trial examining the effects of "third wave" cognitive therapy versus mentalization-based treatment for acute major depressive disorder.
    Jakobsen JC
    Dan Med J; 2014 Oct; 61(10):B4942. PubMed ID: 25283628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.
    Bridge JA; Iyengar S; Salary CB; Barbe RP; Birmaher B; Pincus HA; Ren L; Brent DA
    JAMA; 2007 Apr; 297(15):1683-96. PubMed ID: 17440145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
    Li Z; Liu S; Wu Q; Li J; Yang Q; Wang X; Peng P; Wang Q; Liu Y; Li M; Hao Y; Xu H; He L; Wang Y; Chen S; Liu T
    Int J Neuropsychopharmacol; 2023 Jun; 26(6):373-384. PubMed ID: 37105713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cognitive impairments in patients with depression].
    Schilling TM; Bossert M; Weisbrod M; Aschenbrenner S
    Nervenarzt; 2021 Mar; 92(3):277-288. PubMed ID: 33646323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder.
    Sumiyoshi T; Hoshino T; Mishiro I; Hammer-Helmich L; Ge H; Moriguchi Y; Fujikawa K; Fernandez JL
    J Affect Disord; 2022 Jan; 296():95-102. PubMed ID: 34597893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
    Murthy NV; Xu R; Zhong W; Harvey PD
    J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antidepressants and their effect on cognition in major depressive disorder.
    Papakostas GI
    J Clin Psychiatry; 2015 Aug; 76(8):e1046. PubMed ID: 26335095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.